Form 4: BioLargo Director Marshall Boosts Stock Options

BioLargo Director Dennis E. Marshall received new stock options totaling 242,645 shares at an exercise price of $0.17, compensating for services and replacing expired options.

Summary

• Director Dennis E. Marshall of BioLargo, Inc. (BLGO) was granted 242,645 stock options on September 30, 2025.
• The options have an exercise price of $0.17 per share and expire on September 30, 2035.
• 132,351 of these options replace a previously expired unexercised option for 34,615 shares, issued to compensate for $22,500 in services.
• The remaining 110,294 options were issued as payment for $18,750 in board of directors fees for the most recently completed quarterly period, under the Issuer's 2024 Equity Incentive Plan.
• Following these transactions, Marshall beneficially owns 5,067,561 derivative securities.

Sentiment

Score: 6

Explanation: The filing reports routine director compensation through stock options, which is generally neutral to slightly positive as it aligns director interests with shareholders. The replacement of expired options due to price discrepancy is a minor negative point, but the overall activity is standard.

Positives

• Director Marshall received new stock options, indicating continued compensation and alignment with shareholder interests.
• The company is utilizing its 2024 Equity Incentive Plan for director compensation, a common practice.
• The replacement of expired options for services rendered ensures fair compensation for past contributions.

Negatives

• A previous option for 34,615 shares expired unexercised due to a discrepancy between the original exercise price and the Issuer's current stock price, suggesting the stock price was below the original exercise price at expiration.
• Issuing options for board fees dilutes existing shareholders, though this is a standard practice.

Risks

• The expiration of previous options due to stock price discrepancy highlights potential volatility or underperformance relative to past expectations.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the expiration date of the granted options.

Management Comments

• The option grants were made 'pursuant to plan adopted by the Issuer's Compensation Committee' and 'pursuant to the Issuer's 2024 Equity Incentive Plan,' reflecting adherence to established compensation policies.

Industry Context

The use of stock options as a form of compensation for directors is a standard practice across many industries, aligning management incentives with shareholder value creation. The replacement of expired options due to price discrepancy is less common but can occur in companies with volatile stock performance or long-dated option grants.

Comparison to Industry Standards

• Granting stock options as director compensation is a common practice, comparable to how many public companies, particularly in the biotech or emerging technology sectors like BioLargo, incentivize their board members.
• An exercise price of $0.17, while low, is typical for options granted at or near the market price on the grant date, which is a standard industry practice for incentive options.
• The total number of options granted (242,645) for services and board fees should be evaluated against the company's overall market capitalization and the director's total compensation package to assess if it's within reasonable industry benchmarks for a company of BioLargo's size and stage.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential minor dilution from new option grants, but also improved alignment of director incentives with company performance.
• Employees: No direct impact mentioned, but the 2024 Equity Incentive Plan could also apply to other employees.
• Directors: Dennis E. Marshall received additional equity compensation for services and board fees.

Next Steps

• The options granted on September 30, 2025, will become exercisable on the same date and expire on September 30, 2035.

Key Dates

Recommendation

This Form 4 filing details routine director compensation through stock options and the replacement of previously expired options. It does not contain information significant enough to warrant a change in investment recommendation. The transactions are standard corporate governance activities and do not indicate a material shift in the company's financial health or strategic direction. Investors should continue to hold based on broader company fundamentals and market conditions, not solely on this compensation report.

Keywords

BioLargo, BLGO, Dennis Marshall, Stock Options, Director Compensation, SEC Form 4, Equity Incentive Plan, Beneficial Ownership